Evidence map›Paper›PMID 42426811›Full record

ArticleJournal of translational medicine2026

Cross-layer multiomic and digital pathology analysis identifies a malignant keratinization state linked to immune exclusion in cervical squamous carcinoma.

Xiao Chen, Dongmei Zhou, Yiting Lin, Wanzhen Lin, Zuolian Xie, Lijun Chen, Linying Liu, Yang Sun

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiao Chen *Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China.ORCID 0009-0000-5230-5103
Dongmei Zhou *Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China.
Yiting LinDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China.
Wanzhen LinDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China.
Zuolian XieDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China.
Lijun ChenDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China.
Linying LiuDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China.
Yang SunDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350000, China. dryangsun@126.com.ORCID 0000-0002-1587-9797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune exclusion contributes to heterogeneous benefit from immunotherapy in cervical squamous carcinoma, but the malignant epithelial state most closely associated with this phenotype and its tissue- and morphology-level correlates remain unclear. We investigated whether a lesion-grade-associated malignant epithelial state was linked to immune-excluded tissue architecture and could be translated across transcriptomic and pathology modalities.

methodsWe integrated single-cell RNA-seq discovery (GSE208653), spatial transcriptomic evaluation (GSE208654), bulk RNA-seq translation in primary squamous TCGA-CESC tumors, external whole-tumor evaluation in CGCI-HTMCP-CC, and whole-slide H&E analysis of 259 slides from 250 TCGA patients. External immune-focused datasets, a local neoadjuvant immunotherapy-treated cervical squamous carcinoma cohort, and a representative pilot whole-section multiplex immunofluorescence were used as supportive layers.

resultsA basal-squamous stress keratinization (BSK) program was the malignant epithelial state most consistently associated with the cross-sectional normal-HSIL-squamous carcinoma spectrum. Across four spatial sections, BSK showed a section-consistent core-boundary-shell organization comprising a BSK-rich tumor core, a stromal-myeloid boundary, and a more peripheral lymphoid shell. In primary squamous TCGA-CESC tumors, this biology was translated most clearly into an epithelial-exclusion bulk state associated with fibro-myeloid niche enrichment and weaker engagement of inflamed/dysfunctional CD8 T-cell programs. Patient-level out-of-fold morphology scores from matched TCGA H&E slides correlated positively with epithelial exclusion, supporting a detectable histologic correlate within the matched pathology arm. In a local 18-patient neoadjuvant immunotherapy-treated cohort, H&E-derived morphology scores were associated with postoperative pathological response grade, providing exploratory clinical-pathology support rather than predictive validation. The exclusion-centered ordering was directionally preserved in CGCI-HTMCP-CC and aligned with stromal/EMT/TGFβ, angiogenesis, and more moderate gMDSC-related programs.

conclusionsBSK marks an exclusion-associated cervical squamous carcinoma state that is spatially organized, measurable in bulk transcriptomes, and partially reflected in routine histology. These findings provide a human-data-derived translational framework for future immune-access stratification and prospective biomarker testing but do not establish BSK as a causal driver or validated predictor of immunotherapy response.

Indexed as

Carcinoma, Squamous CellUterine Cervical NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansImmunotherapyMultiomicsBiomarkerCervical squamous carcinomaDigital pathologyImmune exclusionSingle-cell RNA sequencingSpatial transcriptomicsTumor microenvironment

Identifiers

PMID42426811
PMCPMC13397699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.